CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.44 USD | -5.06% |
|
-17.57% | -42.04% |
| Sales 2023 * | 66.26M 70.48M | Sales 2024 * | 87.27M 92.84M | Capitalization | 512M 545M |
|---|---|---|---|---|---|
| Net income 2023 * | -199M -212M | Net income 2024 * | -196M -209M | EV / Sales 2023 * | 1.22 x |
| Net cash position 2023 * | 431M 459M | Net cash position 2024 * | 230M 245M | EV / Sales 2024 * | 3.23 x |
| P/E ratio 2023 * |
-2.42
x | P/E ratio 2024 * |
-2.48
x | Employees | 977 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 54.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on CureVac N.V.
More press releases
More news
| 1 day | -5.06% | ||
| 1 week | -17.57% | ||
| Current month | -19.47% | ||
| 1 month | -23.99% | ||
| 3 months | -32.97% | ||
| 6 months | -55.96% | ||
| Current year | -42.04% |
1 week
2.44
2.92
1 month
2.443.26
Current year
2.444.46
1 year
2.4412.36
3 years
2.44130.48
5 years
2.44151.80
10 years
2.44151.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 23-03-27 | |
Pierre Kemula
DFI | Director of Finance/CFO | 50 | 16-10-31 |
Malte Greune
COO | Chief Operating Officer | 59 | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Tooman
BRD | Director/Board Member | 58 | 19-05-31 |
Michael Brosnan
BRD | Director/Board Member | 69 | 23-06-18 |
| Director/Board Member | 67 | 22-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 17 M€ | -.--% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.44 | -5.06% | 712,915 |
| 24-04-17 | 2.57 | -3.56% | 921,443 |
| 24-04-16 | 2.665 | +0.57% | 474,514 |
| 24-04-15 | 2.65 | -8.93% | 944,201 |
| 24-04-12 | 2.91 | -1.69% | 894,825 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people's lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-04-23
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.288
EUR
Average target price
11.42
EUR
Spread / Average Target
+399.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.04% | 575M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- CVAC Stock
